Cost-effectiveness of Pharmaceutical Interventions to Prevent Osteoporotic Fractures in Postmenopausal Women with Osteopenia
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: To assess the cost-effectiveness of drug therapy to prevent osteoporotic fractures in postmenopausal women with osteopenia in Korea. Methods: A Markov cohort simulation was conducted for lifetime with a hypothetical cohort of postmenopausal women with osteopenia and without prior fractures. They were assumed to receive calcium/vitamin D supplements only or drug therapy (i.e., raloxifene or risedronate) along with calcium/vitamin D for 5 years. The Markov model includes fracture-specific and non-fracture specific health states (i.e. breast cancer and venous thromboembolism), and all-cause death. Published literature was used to determine the model parameters. Local data were used to estimate the baseline incidence rates of fracture in those with osteopenia and the costs associated with each health state. Results: From a societal perspective, the estimated incremental cost-effectiveness ratios (ICERs) for the base cases that had T-scores between -2.0 and -2.4 and began drug therapy at the age of 55, 60, or 65 years were $16,472, $6,741, and -$13,982 per quality-adjusted life year (QALY) gained, respectively. Sensitivity analyses for medication compliance, risk of death following vertebral fracture, and relaxing definition of osteopenia resulted in ICERs reached to $24,227 per QALY gained. Conclusions: ICERs for the base case and sensitivity analyses remained within the World Health Organization’s willingness-to-pay threshold, which is less than per-capita gross domestic product in Korea (about $25,700). Thus, we conclude that drug therapy for osteopenia would be a cost-effective intervention, and we recommend that the Korean National Health Insurance expand its coverage to include drug therapy for osteopenia.
Abstract
Background: To assess the cost-effectiveness of drug therapy to prevent osteoporotic fractures in postmenopausal women with osteopenia in Korea. Methods: A Markov cohort simulation was conducted for lifetime with a hypothetical cohort of postmenopausal women with osteopenia and without prior fractures. They were assumed to receive calcium/vitamin D supplements only or drug therapy (i.e., raloxifene or risedronate) along with calcium/vitamin D for 5 years. The Markov model includes fracture-specific and non-fracture specific health states (i.e. breast cancer and venous thromboembolism), and all-cause death. Published literature was used to determine the model parameters. Local data were used to estimate the baseline incidence rates of fracture in those with osteopenia and the costs associated with each health state. Results: From a societal perspective, the estimated incremental cost-effectiveness ratios (ICERs) for the base cases that had T-scores between -2.0 and -2.4 and began drug therapy at the age of 55, 60, or 65 years were $16,472, $6,741, and -$13,982 per quality-adjusted life year (QALY) gained, respectively. Sensitivity analyses for medication compliance, risk of death following vertebral fracture, and relaxing definition of osteopenia resulted in ICERs reached to $24,227 per QALY gained. Conclusions: ICERs for the base case and sensitivity analyses remained within the World Health Organization’s willingness-to-pay threshold, which is less than per-capita gross domestic product in Korea (about $25,700). Thus, we conclude that drug therapy for osteopenia would be a cost-effective intervention, and we recommend that the Korean National Health Insurance expand its coverage to include drug therapy for osteopenia.
참고문헌 (40)
- "Prevention and management of osteoporosis" (2003)[URL]
- Looker AC, "Prevalence of low femoral bone density in older U.S. adults from NHANES III", J Bone Miner Res, 12, pp.1761~1768 (1997)
- National Evidence-based Healthcare Collaborating Agency, "Developing Korea-specific assessment criteria for osteoporosis", National Evidence-based Healthcare Collaborating Agency, ~ (2011)
- Siris ES, "Effects of risedronate on fracture risk in postmenopausal women with osteopenia", Osteoporos Int, 19, pp.681~686 (2008)
- Siris ES, "Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women : results from the National Osteoporosis Risk Assessment", JAMA, 286, pp.2815~2822 (2001)
- Schuit SC, "Fracture incidence and association with bone mineral density in elderly men and women : the Rotterdam study", Bone, 34, pp.195~202 (2004)
- 이재협, "Association between Bone Mineral Density and Clinical Consequences: Cross-Sectional Study of Korean Postmenopausal Women in an Orthopaedic Outpatient Clinic", Journal of Korean Medical Science, 29(8), pp.1152~1160 (2014), 대한의학회
- Pasco JA, "The population burden of fractures originates in women with osteopenia, not osteoporosis", Osteoporos Int, 17, pp.1404~1409 (2006)
- Siris ES, "Bone mineral density thresholds for pharmacological intervention to prevent fractures", Arch Intern Med, 164, pp.1108~1112 (2004)
- Kanis JA, "Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis : a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial", Bone, 33, pp.293~300 (2003)
- Jolly EE, "Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years", Menopause, 10, pp.337~344 (2003)
- Ivergård M, "Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer", Bone, 47, pp.966~974 (2010)
- Kanis JA, "Cost-effectiveness of raloxifene in the UK : an economic evaluation based on the MORE study", Osteoporos Int, 16, pp.15~25 (2005)
- Wasserfallen JB, "Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women : a Swiss perspective", J Med Econ, 11, pp.499~523 (2008)
- Zethraeus N, "Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model", Osteoporos Int, 18, pp.9~23 (2007)
- Kanis JA, "Cost-effectiveness of preventing hip fracture in the general female population", Osteoporos Int, 12, pp.356~361 (2001)
- Borgström F, "Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden : an economic evaluation based on the MORE study", Pharmacoeconomics, 22, pp.1153~1165 (2004)
- Kang HY, "Incidence and mortality of hip fracture among the elderly population in South Korea : a population-based study using the national health insurance claims data", BMC Public Health, 10, pp.230~ (2010)
- Meadows ES, "Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia", BMC Womens Health, 7, pp.6~ (2007)
- Klotzbuecher CM, "Patients with prior fractures have an increased risk of future fractures : a summary of the literature and statistical synthesis", J Bone Miner Res, 15, pp.721~739 (2000)
- Annual report of cancer statistics in Korea in 2010, "The Korea Central Cancer Registry, National Cancer Center", Ministry of Health and Welfare, ~ (2012)
- "2006-2008 Breast cancer facts & figures" (2008)[URL]
- "2012 Breast cancer facts & figures" (2012)[URL]
- Martino S, "Continuing outcomes relevant to Evista : breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene", J Natl Cancer Inst, 96, pp.1751~1761 (2004)
- Grady D, "Safety and adverse effects associated with raloxifene : multiple outcomes of raloxifene evaluation", Obstet Gynecol, 104, pp.837~844 (2004)
- Weycker D, "Compliance with drug therapy for postmenopausal osteoporosis", Osteoporos Int, 17, pp.1645~1652 (2006)
- Yoon SP, "Quality of life in patients with osteoporotic vertebral fractures", Asian Spine J, 8, pp.653~658 (2014)
- Kim JK, "Evaluation of the Korean version of the patient-rated wrist evaluation.", J Hand Ther, 26, pp.238~243 (2013)
- Guillemin F, "Fear of falling, fracture history, and comorbidities are associated with health-related quality of life among European and US women with osteoporosis in a large international study", Osteoporos Int, 24, pp.3001~3010 (2013)
- Korean Society for Bone and Mineral Research, "Physician’s guide for diagnosis & treatment of osteoporosis", Korean Society for Bone and Mineral Research, ~ (2013)
- Kang HY, "Estimating medical expenditure associated with osteoporotic hip fracture in elderly Korean women based on the National Health Insurance Claims Database 2002-2004", Value Health, 12(Suppl 3), pp.S93~S96 (2009)
- Health Insurance Review and Assessment Service, "Cost estimation from diagnosis to death of cancer patients", Health Insurance Review and Assessment Service, ~ (2010)
- Medical service utilization and cost among Korean elderly in the period of last twelve months of life, "Ministry for Health WaFA", Ministry for Health, Welfare and Family Affairs, ~ (2001)
- "Cost effectiveness and strategic planning (WHO-CHOICE)" (2015)[URL]
- Müller D, "Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia : a systematic review", Value Health, 15, pp.284~298 (2012)
- Schwenkglenks M, "Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland", Osteoporos Int, 18, pp.1481~1491 (2007)
- Schousboe JT, "Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy", Osteoporos Int, 18, pp.201~210 (2007)
- Schousboe JT, "Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study", J Clin Densitom, 9, pp.133~143 (2006)
- Eisman JA, "Making the first fracture the last fracture : ASBMR task force report on secondary fracture prevention", J Bone Miner Res, 27, pp.2039~2046 (2012)
- Rose G, "Sick individuals and sick populations", Int J Epidemiol, 14, pp.32~38 (1985)